Truveta was founded in 2020 by former Microsoft Windows chief Terry Myerson, alongside a coalition of major US health systems, on the premise that the richest source of real-world clinical insight, electronic health records, is fragmented and largely inaccessible for research. Truveta unifies and de-identifies EHR data from its member health systems into a single, continuously updated, standardized database that today represents more than 120 million patients and a meaningful share of all daily clinical care delivered in the United States.
The company's flagship product, Truveta Studio, gives researchers an AI-enabled environment to query this data, build patient cohorts, and analyze outcomes across conditions, treatments, and populations. Because the data is fed by health systems that are also equity stakeholders, Truveta aligns the incentives of providers, researchers, and life sciences partners around responsible, privacy-preserving use of clinical data to improve care and accelerate medical discovery.
Life sciences companies use Truveta to design and recruit clinical trials, conduct post-market safety surveillance, and generate real-world evidence for regulators. Health systems use it to benchmark care quality and study their own populations. The platform's AI capabilities extract structured insight from messy clinical notes, imaging, and lab data that would otherwise be unusable at scale.
In January 2025, Truveta closed a $320 million Series C that pushed it to unicorn status at a roughly $1 billion valuation. The round included strategic investments from Illumina and Regeneron, alongside 17 health systems such as Northwell Health and Trinity Health. The capital funds the Truveta Genome Project, an effort to sequence the exomes of up to ten million consented, de-identified volunteers and link genetic data to the clinical record, creating one of the largest genotype-phenotype resources in the world.
Headquartered in the Seattle area, Truveta sits at the intersection of health data infrastructure, AI, and genomics, positioning it as a foundational platform for the next generation of medical research.